Objective. Roux-en-Y gastric bypass (RYGB) is an independent risk factor for moderate hypocalcaemia and may lead to the development of resistant hypocalcaemia following thyroid surgery.
Hypocalcaemia is a well-defi ned complication of thyroid surgery, which develops as a result of temporary or permanent injury of the parathyroid glands (Delbridge et al. 1999 ). Roux-en-Y gastric bypass (RYGB) is an independent risk factor for moderate hypocalcaemia related to the decreased production of gastric acid and the absorption of calcium and vitamin D by the intestinal surface (Slater et al. 2004) . Th is condition may lead to the development of resistant hypocalcaemia following thyroid surgery in patients with a history of RYGB. Th is report presents a case history of RYGB and resistant hypocalcaemia, which developed aft er thyroid surgery but responded well to pancrelipase treatment.
Subject and Results
A 35-year old female patient was referred to our hospital by her family physician for treatment of resistant hypocalcaemia. Th e patient underwent RYGB three years ago and a total thyroidectomy for a benign thyroid nodule one year ago.
At the time of her admission, the laboratory parameters were as follows: calcium (Ca): 7.1 mg/dl; phosphorus (P): 4.4 mg/dl; magnesium (Mg): 1.70 mg/dl; 25-hydroxyvitamin D [25(OH)D]: 18 ng/ml; parathormone (PTH): 9 pg/ml; thyroid stimulating hormone (TSH): 3.2 μIU/ml; albumin: 4.2 g/dl. To the patient levothyroxine 100 μg/day, calcitriol 1 μg/day, and calcium carbonate 4 g/day was prescribed. Th e treatment scheme of the patient was as follows: calcitriol 2 μg/day, calcium carbonate 6 g/day, magnesium oxide 400 mg 1×1, ergocalciferol 50 000 IU/day for one week followed by 50 000 IU/14 days, sunlight exposure (20 min per day), and a recommended diet.
Th e control biochemical values obtained aft er one month of treatment were as follows: Ca: 7.2 mg/dl, P: 4.2 mg/dl; Mg: 1.98 mg/dl; 25(OH)D: 27 ng/ml. Th e treatment scheme was: calcitriol 3 μg/day and calcium carbonate 8 g/day. Th e control biochemical parameters obtained aft er two months of treatment were as follows: Ca: 7.4 mg/dl; P: 4.0 mg/dl; Mg:
1.96 mg/dl; 25(OH)D: 38 ng/ml. Despite dosage increments in two subsequent visits, the expected results of the treatment were not achieved.
In the sixth month aft er admission to our hospital, the patient's treatment scheme was as follows: calcitriol 6 μg/day, calcium carbonate 12 g/day, and ergocalciferol 50,000 IU/30 days. Pancrelipase (8000 USP units of amylase, 10 000 USP units of lipase, and 600 USP units protease) (three times a day with meals) was added to the treatment regimen. On the following visit, a good calcium increase had been achieved (Ca: 9.0 mg/dl, P: 3.9 mg/dl). Decrements in calcitriol, calcium carbonate, and ergocalciferol dosages were 
Discussion
Bariatric surgery procedures have been increasingly performed worldwide during the last ten years. About 200 000 bariatric surgery operations are performed in United States annually (Kohn et al. 2009; Lo Menzo et al. 2015) . Th e most common procedure is RYGB, which comprises about 80% of all bariatric surgery cases (Kohn et al. 2009; Lo Menzo et al. 2015) .
RYGB is a malabsorptive bariatric surgical method in which the duodenum and jejunum are bypassed. Most parts of the stomach and ileum are bypassed by anastomosing the distal ileum to a small gastric pouch. It is known that malabsorptive procedures such as RYGB may cause a wide range of nutritional defi ciencies, including protein, iron, vitamin B 12 , folic acid, calcium, magnesium, vitamin D, and other fat soluble vitamins (Toh et al. 2009 ).
Dietary calcium is mainly absorbed by the duodenum and proximal jejunum (Slater et al. 2004 ). In the case of low dietary calcium intake in a healthy adult, 80-100% of calcium may be absorbed by the duodenum via a vitamin-D dependent transcellular active transport mechanism (Johnson et al. 2006) . However, if the duodenum is by-passed, calcium is absorbed by a less eff ective paracellular transport mechanism, which is located in the ileum. It normally contributes from 0-20% to calcium absorption (Johnson et al. 2006) . Another mechanism by which RYGB disturbs calcium absorption is low acidity in the formed gastric pouch compared to normal gastric content (Miller and Smith 2006) . In addition, patients who undergo bariatric surgery have fat malabsorption due to the insuffi cient mixture of biliary salts and dietary fat, which causes defi ciencies in mainly vitamin D and other fat-soluble vitamins (Johnson et al. 2006) .
Vitamin D defi ciency and insuffi ciency are very common in obese individuals, independent of bariatric surgery (Bischof et al. 2006; Carlin et al. 2006 ). In obese people, both cutaneous vitamin D synthesis and the intestinal absorption of dietary vitamin D intake are decreased (Wortsman et al. 2000) . Dietary vitamin D is mainly absorbed by the jejunum and ileum (Bloomberg et al. 2005) , and in obese individuals, the intestinal absorption of vitamin D further decreases aft er RYGB.
In addition to these causes, it is known that following bariatric surgery patients take only half of the amount of daily-recommended vitamin D and in many patients intolerance to calcium-rich foods aft er surgery develops (Salinger and Moore 2010; Nguyen et al. 2011) . Consequently, these patients become prone to vitamin D defi ciency and calcium metabolism disorder. In the fi rst four years following bariatric surgery, the incidences of hypocalcaemia and vitamin D defi ciency are 15-48% and 50-63%, respectively, independent of multi-vitamin support (Hundahl et al. 2000; Tondapu et al. 2009 ). For this reason, current guidelines have recommend calcium (1200 mg/day) and 25(OH)D (800 IU/day) for patients aft er bariatric surgery (Mechanick et al. 2008) .
Th yroidectomy is a commonly performed surgical procedure with a low complication rate. Hypocalcaemia is a well-defi ned complication of thyroid surgery. Although a wide range of statistical values has been reported in the literature, hypocalcaemia develops in about 10% of patients and permanent hypoparathyroidism requiring long-term calcium supplementation occurs in about 1% of patients (Delbridge et al. 1999; Hundahl et al. 2000) . In the case of RYGB-related hypocalcaemia, normocalcaemia may be achieved by secondary hyperparathyroidism. However, this compensation mechanism does not work in the case of iatrogenic hypoparathyroidism. Th erefore, total thyroidectomy is a risk factor for the development of resistant hypocalcaemia in patients with a history of RYGB surgery.
Case histories of patients who developed resistant hypocalcaemia secondary to total thyroidectomy aft er RYGB surgery have been reported in the literature (Durr et al. 2009; Pietras and Holick 2009; Salinger and Moore 2010; Gross et al. 2014; Panazzolo et al. 2014; Alfonso et al. 2015) . Unlike other cases, Panazzolo et al. (2014) have used pancrelipase in the treatment, speculating that it might enhance the absorption of fat and fat soluble vitamins (especially vitamin D), and they obtained a successful result. Th e only relevant original research found in the literature is a retrospective study conducted by McKenzie et al. (2013) . In this study, data of 19 patients who underwent thyroidectomy aft er RYGB were compared with the data of a control group. Th e incidences of symptomatic hypocalcaemia, postoperative intravenous calcium requirement, and duration of hospitalization, were found to be signifi cantly higher in the patients underwent to thyroidectomy (McKenzie et al. 2013) .
It has been shown that calcium citrate was better absorbed than calcium carbonate aft er gastric bypass because of low acid secretion (Johnson et al. 2006) . Because calcium citrate is not available in our country, we used calcium carbonate in oral calcium treatment in our case. Th iazid diuretics decreased the excretion of urinary calcium by increasing calcium absorption by the distal tubule. Testa et al. (2006) have suggested that calcitriol and a low dosage of thiazid diuretic treatment were protective against hypocalcaemia aft er thyroid surgery. Because the urinary calcium levels in our patient were low and thiazid treatment was not tested on this patient group, we did not apply thiazid diuretic treatment in this case. Although high dosages of oral calcium and vitamin D (calcitriol and cholecalciferol) treatment were given and magnesium was added to the treatment, a suffi cient treatment response was not achieved. For this reason, we applied the pancrelipase treatment, which has previously been reported by Panazzolo et al. (2014) . A quite good treatment response was obtained with pancrelipase, the desired calcium levels were achieved and the dosages of other drugs were partially decreased.
Th e treatment of iatrogenic hypoparathyroidism in patients with RYGB history may create diffi culties for physicians. In addition to standard calcium and vitamin D replacement treatment, pancrelipase may be utilized in resistant cases. Pancrelipase may have a positive eff ect on calcium absorption by increasing the absorption of vitamin D. Further controlled trials are required to determine the importance and appropriateness of pancrelipase treatment in this patient group.
